M K Eriksen1, L L Thomsen, J Olesen. 1. Danish Headache Center, University of Copenhagen, Department of Neurology, Glostrup Hospital, Nordre Ringvej 57, DK-2600 Glostrup, Denmark. kirchmann@dadlnet.dk
Abstract
OBJECTIVES: Since 1998, migraine with aura (MA) has been diagnosed according to the operational diagnostic criteria of the International Headache Society (ICHD-1). Here we present the data underlying the new criteria for MA in the ICHD-2 classification. METHODS: Sensitivity of the new criteria was tested in patients with MA and specificity in patients with reversible non-aura visual disturbances. The diagnoses in both groups of patients were made in a validated semistructured physician-conducted interview. We tested five sets of criteria for sensitivity and specificity comparing with the diagnosis according to the ICHD-1 in 200 patients and the selected set of criteria in 274 additional patients. RESULTS: Four sets of criteria had sensitivity/specificity of 46%/100%, 71%/100%, 62%/95%, and 99%/76%. Sensitivity of the selected set of criteria was 84% (95% CI 79% to 90%) and specificity 97% (95% CI 95% to 99%). According to these criteria at least two of the following should be fulfilled: homonymous visual or unilateral sensory symptoms; at least one aura symptom develops gradually over > or =5 minutes and/or different symptoms occur in succession over > or =5 minutes; each symptom lasts > or =5 and < or =60 minutes. In the additional sample sensitivity of the selected criteria was 90% (95% CI 86% to 94%) and specificity 96% (95% CI 91% to 100%). CONCLUSIONS: The diagnostic criteria for MA selected for ICHD-2 had high sensitivity and specificity. The ICHD-2 criteria are more operational and probably delineate a more homogeneous sample of patients than the ICHD-1. The ICHD-2 for MA is intended equally for research and clinical practice and can be used at different levels of specialisation.
OBJECTIVES: Since 1998, migraine with aura (MA) has been diagnosed according to the operational diagnostic criteria of the International Headache Society (ICHD-1). Here we present the data underlying the new criteria for MA in the ICHD-2 classification. METHODS: Sensitivity of the new criteria was tested in patients with MA and specificity in patients with reversible non-aura visual disturbances. The diagnoses in both groups of patients were made in a validated semistructured physician-conducted interview. We tested five sets of criteria for sensitivity and specificity comparing with the diagnosis according to the ICHD-1 in 200 patients and the selected set of criteria in 274 additional patients. RESULTS: Four sets of criteria had sensitivity/specificity of 46%/100%, 71%/100%, 62%/95%, and 99%/76%. Sensitivity of the selected set of criteria was 84% (95% CI 79% to 90%) and specificity 97% (95% CI 95% to 99%). According to these criteria at least two of the following should be fulfilled: homonymous visual or unilateral sensory symptoms; at least one aura symptom develops gradually over > or =5 minutes and/or different symptoms occur in succession over > or =5 minutes; each symptom lasts > or =5 and < or =60 minutes. In the additional sample sensitivity of the selected criteria was 90% (95% CI 86% to 94%) and specificity 96% (95% CI 91% to 100%). CONCLUSIONS: The diagnostic criteria for MA selected for ICHD-2 had high sensitivity and specificity. The ICHD-2 criteria are more operational and probably delineate a more homogeneous sample of patients than the ICHD-1. The ICHD-2 for MA is intended equally for research and clinical practice and can be used at different levels of specialisation.
Authors: D P Bradley; M I Smith; C Netsiri; J M Smith; K H Bockhorst; L D Hall; C L Huang; R A Leslie; A A Parsons; M F James Journal: Exp Neurol Date: 2001-12 Impact factor: 5.330
Authors: Maija Wessman; Mikko Kallela; Mari A Kaunisto; Pia Marttila; Eric Sobel; Jaana Hartiala; Greg Oswell; Suzanne M Leal; Jeanette C Papp; Eija Hämäläinen; Petra Broas; Geoffrey Joslyn; Iiris Hovatta; Tero Hiekkalinna; Jaakko Kaprio; Jürg Ott; Rita M Cantor; John-Anker Zwart; Matti Ilmavirta; Hannele Havanka; Markus Färkkilä; Leena Peltonen; Aarno Palotie Journal: Am J Hum Genet Date: 2002-02-08 Impact factor: 11.025
Authors: L Lykke Thomsen; M Kirchmann Eriksen; S Faerch Romer; I Andersen; E Ostergaard; N Keiding; J Olesen; M B Russell Journal: Cephalalgia Date: 2002-06 Impact factor: 6.292
Authors: Jakob M Hansen; Richard B Lipton; David W Dodick; Stephen D Silberstein; Joel R Saper; Sheena K Aurora; Peter J Goadsby; Andrew Charles Journal: Neurology Date: 2012-10-31 Impact factor: 9.910